All Search Results
News Releases
Jun 09, 2026, 09:10 ET Parker Waichman LLP Files Lawsuit on behalf of Massachusetts Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy
concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks.A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from
More news about: Parker Waichman LLP
Jun 09, 2026, 08:08 ET Selagine Plasma to Advance Pooled Plasma Eye Drops for Moderate-to-Severe Dry Eye
moderate-to-severe dry eye disease," said Sandeep Jain, MD, founder and Chief Executive Officer of Selagine Plasma and B.A. Field Professor of Ophthalmology at the University of Illinois Chicago. "The opportunity is not simply to create another tear substitute. The opportunity is to build a standardized,
More news about: Selagine, Inc.
Jun 08, 2026, 16:10 ET Visage Highlights One Platform AI-Optimized at SIIM26
solution in Enterprise Imaging. With Visage 7, customers can display, distribute and manage all Radiology, Breast Imaging, Cardiology, Pathology, Ophthalmology, Dental, OB US, POCUS, Visible Light Photos, Video, and PDFs, regardless of the size of the studies, with the ability to support orders and encounters-based
More news about: Visage Imaging, Inc.
Jun 08, 2026, 04:30 ET 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, presented multiple clinical and preclinical results of its innovative metabolic and obesity pipeline at the 2026 American
More news about: Innovent Biologics
Jun 04, 2026, 16:03 ET B. Riley Securities to Host Mind, Muscle & Vision Healthcare Summit on July 16, 2026
award-winning equity research team, ensuring investors access to differentiated opportunities across psychiatry, neurology, neuromuscular, cardiology, and ophthalmology – many poised for meaningful commercial, clinical trial, and regulatory catalysts into 2027.The summit will feature research analyst-hosted
More news about: B. Riley Securities
